Fighting for new cath lab safety standards | FDA confirms Impella recall | ‘Practice-changing’ research | Heart failure & PCI

Several U.S. medical societies have collaborated on a new report advocating for better safety standards in cardiac catheterization labs. As one cardiologist described it, clinicians have shifted from "accepting risk" to "expecting better."

More than 33,000 devices are affected by this recall. Customers may need to return and replace the purge cassettes included with their devices due to a risk of serious injury or death. 

The second day of the American College of Cardiology’s annual conference started with a series of highly anticipated interventional cardiology trials.

Lerman, who spent nearly 40 years with Mayo Clinic, was especially influential in the treatment of nonobstructive CAD. 

CRT studies shed new light on many topics, including long-term TAVR outcomes, radiation protection and advanced interventional techniques.

Philips worked closely with Edwards Lifesciences to develop the new software.

A prominent figure in the fields of interventional cardiology and women’s health is now leading the American College of Cardiology.

Nonfatal adverse events after PCI are associated with an increased risk of two-year mortality. That risk is especially high, it seems, when patients are hospitalized for heart failure symptoms such as shortness of breath and edema. 

The TRiCares Topaz uses a unique two-stent frame valve prosthesis for better sealing and flexibility.